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Abstract
In patients with sepsis, liver metabolism and its capacity to provide other organs with energetic substrates are impaired. This and many
other pathophysiological changes seen in human patients are reproduced in mice injected with purified endotoxin (lipopolysaccharide, LPS).
In the present study, down-regulation of genes involved in hepatic fatty acid oxidation (FAOx) and gluconeogenesis in mice exposed to
LPS was challenged by nutritional intervention with Argan oil. Mice given a standard chow supplemented or not with either 6% (w/w)
Argan oil (AO) or 6% (w/w) olive oil (OO) prior to exposure to LPS were explored for liver gene expressions assessed by mRNA
transcript levels and/or enzyme activities. AO (or OO) food supplementation reveals that, in LPS-treated mice, hepatic expression of genes
involved in FAOx and gluconeogenesis was preserved. This preventive protection might be related to the recovery of the gene expressions
of nuclear receptors peroxisome proliferator-activated receptor α (PPARα) and estrogen related receptor α (ERRα) and their coactivator
peroxisome proliferator-activated receptor gamma coactivator-1α, (PGC-1α). These preventive mechanisms conveyed by AO against LPS-
induced metabolic dysregulation might add new therapeutic potentialities in the management of human sepsis.
© 2015 The Authors. Published by Elsevier B.V. on behalf of Société Française de Biochimie et Biologie Moléculaire (SFBBM).
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Argan oil; Beta-oxidation; Coactivator; Gluconeogenesis; Nuclear receptor.
a
l
g
p
O
h
2
aAbbreviations: ACADS, acyl CoA dehydrogenase short-chain; ACADM,
cyl CoA dehydrogenase medium-chain; ACADL, acyl CoA dehydrogenase
ong-chain; AO, Argan oil; ACOX1, acyl-CoA oxidase 1; ERRα, estro-
en related receptor α; G6PH, glucose-6-phosphatase; Glut2, glucose trans-
orter 2; Glut4, glucose transporter 4; HNF-4α, hepatic nuclear factor-4α;
O, olive oil; LPS, lipopolysaccharide; PGC-1α, peroxisome proliferator-
a
n
B
2
ttp://dx.doi.org/10.1016/j.biopen.2015.10.002
214-0085/© 2015 The Authors. Published by Elsevier B.V. on behalf of Société
ccess article under the CC BY-NC-ND license (http://creativecommons.org/licensctivated receptor γ coactivator-1α; PEPCK, phospoenolpyruvate carboxyki-
ase; PPARα, peroxisome proliferator-activated receptor α.
∗ Corresponding author. Laboratoire BioPeroxIL EA7270, Univ.
ourgogne-Franche Comté, Faculté des Sciences Gabriel, 6 Bd Gabriel,
1000 Dijon, France. Tel.: +33 380396205.
E-mail address: malki@u-bourgogne.fr (M. Cherkaoui-Malki).
Française de Biochimie et Biologie Moléculaire (SFBBM). This is an open
es/by-nc-nd/4.0/).
52 R. El Kebbaj et al. /Biochimie Open 1 (2015) 51–59
h
a
t
t
k
r
A
d
n
g
c
w
e
s
c
t
t
c
m
a
t
d
j
b
a
t
d
L
t
t
(
g
2
2
C
t
l
p
1
o
g
d
w
s
w
a
f
a
t
(
e1. Introduction
Bacterial infection is a common cause of sepsis, a patholog-
ical state inducing a severe organ dysfunction and a high mor-
tality rate, and requiring intensive care [1–3]. This acute syn-
drome is associated with systemic inflammation and disturbed
metabolism [4,5]. During bacterial infection, release in the host
of endotoxins (lipopolysaccharides, LPS) from gram-negative
bacteria membrane generates a potent inflammatory cytokine re-
sponse and severely impairs lipid metabolism, inducing reduced
serum high density lipoprotein (HDL), increased plasma free
fatty acids and triglycerides levels [3]. These metabolic changes
are mainly accounted for by enhanced hepatic triglyceride syn-
thesis and adipose tissue lipolysis combined with a drop in fatty
acid oxidation (FAOx) in several tissues including heart, kidney,
liver and skeletal muscle [3,6–10]. The downregulation of FAOx
by LPS is correlated with decreased expressions of the nuclear
receptor Peroxisome Proliferator-Activated Receptor (PPAR)α
and its coactivator PPARγ Coactivator (PGC)-1α, which phys-
iologically work in concert to regulate FAOx-related gene ex-
pressions [11,12]. In this respect, ligand-dependent activation of
the nuclear receptor PPARα prompts its heterodimerization with
Retinoid X Receptor (RXR)α [13,14]. The PPARα/RXRα com-
plex binds to PPARα-response elements (PPRE) of target genes
which may code for mitochondrial and peroxisomal enzymes
involved in fatty acid β-oxidation pathways such as carnitine
palmitoyl transferase 1 (CPT1a and CPT1b), short-, medium-,
long- and very long-chain acyl CoA dehydrogenases (ACADS,
ACADM, ACADL and ACADVL) [15–19], acyl-CoA oxi-
dase 1 (ACOX1) [17,20,21] and other proteins [12,22]. On the
other hand, Lipin-1, a phosphatidate phosphatase, has arisen
as an additional transcriptional co-regulator of PPARα–PGC-
1α-directed gene expression [23]. Its interaction with PPARα-
PGC1α complex promotes the induction of FAOx genes [24].
Beside PPARα, estrogen related receptor (ERR) α or (ESRRα),
an orphan nuclear receptor, has been also shown to regulate en-
ergy metabolism gene expression [25,26], particularly genes in-
volved in FAOx [27,28]. This transcriptional regulation involves
interaction with PCG-1α coactivator through a protein motif
specifically dedicated to ERRα [29,30]. In liver, another inter-
action of PGC-1α is also observed for hepatic nuclear factor-
4α (HNF-4α) to control genes coding gluconeogenesis pro-
teins (phospoenolpyruvate carboxykinase (PEPCK), glucose-
6-phosphatase (G6PH)) and glucose transporter 4 (Glut4)
[31].
More than 20% of patients with sepsis develop liver dys-
function [1] and hence dysregulation of hepatic metabolism and
reduced energy supply for other organs. In mouse models of
sepsis, injection of purified LPS triggers many pathophysiolog-
ical changes resembling those described in human patients [32].
Though down-regulatory mechanisms by which LPS impacts
FAOx have been extensively studied, little attention has been ac-
tually paid to mechanisms capable of preserving normal FAOx
and inflammation status. Interestingly, supplementation of par-
enteral nutrition with fish oil to patients, during the postoperative
period, revealed lowest levels of circulating inflammatory medi-
ators [33–35]. Accordingly, polyunsaturated fatty acid-rich dietas been reported to reduce acute inflammation and to promote
nti-inflammatory process in mice [36]. Therefore, lipid nutri-
ional support might help the prevention of not only inflamma-
ory damages but also disrupted lipid homeostasis.
Argan edible oil (AO) is obtained by cold-pressure of roasted
ernels from Argania spinosa [L.] Skeels, a singular Mediter-
anean species growing in the southwestern region of Morocco.
rgan oil is used as a traditional food ingredient in the ‘Amazigh
iet’, bringing almost 25% of total diet fat intake to indige-
ous consumers [37]. Accordingly, early clinical studies on Ar-
an oil reported a decrease in plasma low density lipoprotein-
holesterol (LDL-cholesterol) and lipid hydroperoxides along
ith a rise in plasma tocopherol concentration [38]. Health ben-
fits of this delectable virgin oil have been highlighted by several
tudies documenting its cardiovascular protective potential in-
luding hypocholesterolemic and hypotriglyceridemic proper-
ies in consumer populations [39–41]. AO has been also shown
o reduce circulating LDL-cholesterol and ApoB and, in AO
onsumers, to increase HDL and ApoAI [40,41] whereas in hu-
an macrophages it increases HDL-mediated cholesterol efflux
nd reduces LDL-lipid peroxidation [38,39].
Therefore, in an attempt to test our hypothesis regarding
he preventive effects of Argan oil against LPS-induced FAOx
ownregulation, mice pretreated with AO were subsequently in-
ured by LPS to determine whether an experimental support may
e or not given to this working hypothesis. The effects of AO
gainst sepsis-associated liver hyperlipidemia are compared to
hose of olive oil (OO), a more usual ingredient in Mediterranean
iets. We report here that, in fact, AO-enriched diet prevents
PS-associated hyperlipidemic effect through the induction of
he hepatic expressions of PPARα, ERRα and their coactiva-
or PGC-1α along with the up-regulation of their mitochondrial
ACADS, ACADM, ACADVL) and peroxisomal (ACOX1) target
enes.
. Material and methods
.1. Argan oil treatment
Swiss OF1 mice (12–16 week-old) were obtained from IFFA
REDO (Casablanca). They were acclimatized in the labora-
ory for 10 days at 22 ± 2 °C with standard chow and water ad
ibitum. Animal studies were conducted in accordance with the
rotocols of Animal Use and Care of the University of Hassan
st, Settat, Morocco. The virgin Argan oil used in this work was
btained from the Aklim area in the northeast of Morocco. Six
roups of mice (5 mice/group) received during 25 days: a stan-
ard chow (2 groups, control); a standard chow supplemented
ith 6% (w/w) of Argan oil (2 groups, AO) or a standard chow
upplemented with 6% (w/w) of olive oil (2 groups, OO). Oils
ere included in the diets by direct mixing with the standard
nimal chow. Sixteen hours before euthanasia and during the
ed state, one group from control (+LPS), AO (AO + LPS)
nd OO (OO + LPS) respectively received (5 mg/kg) intraperi-
oneal injections of 100 μg of Escherichia coli 0111:B4 LPS
Sigma) resuspended in phosphate-buffered saline (PBS) or an
qual volume of PBS alone.
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h.2. Composition of oils
Both Argan and olive oils (AO and OO) contain mono and
olyunsaturated fatty acids. However, Argan oil has 35% of
18:2n-6 and 45% of C18:1n-9 while olive oil shows only 6%
f C18:2n-6 and more than 75% of C18:1n-9, leading to a higher
nsaturation index of AO (120.4) versus OO (108.3) [42].
.3. Quantitative PCR analysis
Total RNA from liver was extracted using the RNeasy Mini
it (Qiagen) following the manufacturer’s instructions. cDNA
as generated by reverse transcription using Moloney Murine
eukemia Virus Reverse Transcriptase (Promega) according
o the manufacturer’s protocol and analyzed by quantitative
CR using the GoTaq® qPCR Master Mix (Promega), and a
tepOnePlus Real-Time PCR System (Applied Biosystem). The
rimer sequences were chosen using the Beacon Designer Soft-
are (Bio-Rad). Oligonucleotide sequences are shown in the
upplementary Table 1. PCR reactions were carried out in dupli-
ate in a final volume of 12.5 μL containing 6.25 μL of MESA
reen qPCR Master mix (Eurogentec), 2.5 μL of cDNA and
orward and reverse primers at 300 nM. The PCR enzyme (Taq
NA polymerase) was heat-activated at 95 °C for 10 min, and
he DNA was amplified for 40 cycles at 95 °C for 15 s, 60 °C for
0 s, and 72 °C for 30 s, followed by a melting curve analysis
o control the absence of nonspecific products. For each tran-
cript, the amplification efficiency was determined by the slope
f the standard curve generated from two fold serial dilutions of
DNA. Gene expression was quantified using cycle to threshold
Ct) values and normalized by the reference gene, 36B4 en-
oding the acidic ribosomal phosphoprotein P0. To this end,
he quantitative gene expression was determined according to
−Ct with Ct = (Ct of the gene studied) – (Ct of the 36B4
ene).
.4. Enzymatic activity measurements
One hundred mg of liver tissue were homogenized by a
otter-Elvehjm homogenizer in 0.2 ml of a buffer containing
50 mmol/L sucrose, 20 mmol/L Tris–HCl pH 7.5 and 2 mmol/L
DTA. After centrifugation at 600 g for 5 min at 4 °C, the super-
atant was collected and stored at −80 °C until use. Peroxisomal
cyl-CoA oxidase (ACOX1) activity was measured by the fluo-
ometric assay using palmitoyl-CoA as a substrate as described
reviously [43]. Catalase activity was monitored at 240 nm as
escribed elsewhere [44]. Mitochondrial acyl-CoA dehydroge-
ases activities were followed at 600 nm on acyl-CoAs of dif-
erent chain lengths (for experimental details, see legends to
gures) [45].
.5. Statistical analysis
Statistical analyses to compare two experimental groups were
erformed with, an unpaired, two-tailed, Student-t test (Excel
oftware) for calculating the probability values and data were
onsidered statistically different at a P-value of 0.05 or less.. Results
.1. Body weight under experimental diets
Fig. S1 shows the time-course of body weights evolution
uring the nutritional intervention. Each group of mice was
eighted at four different time points during the 3 weeks that
recede the LPS administration; no significant differences in
ody weight have been found between the different experimen-
al groups.
.2. Argan oil modulates the expression of PPARα, PGC-1α
nd related target genes
Interestingly, polyunsaturated fatty acids are known to be
ctivators of PPARα, a nuclear receptor which governs lipid
etabolism and fatty acid oxidation [46]. Here we report
Fig. 1A) that mice treated with AO or OO showed a signifi-
ant increase in hepatic PPARα mRNA, while the mRNA ex-
ression of ERRα displayed no significant variation (Fig. 1B).
ntriguingly, the expression of PGC-1α mRNA was specifically
own regulated by AO (Fig. 1C). However, the expression of
PARα target genes (i.e. ACOX1 and ACADM) was clearly in-
uced by both AO and OO, while ACADS mRNA level was only
ncreased by AO (Fig. 1E, F). Regarding the mitochondrial fatty
cid beta-oxidation activities, only short (C4:0)-, long (C12:0)-
nd very long (C16:0)-acyl-CoA mitochondrial dehydrogenases
ere increased but not the medium (C:8) acyl-CoA dehydroge-
ase activity (Fig. 2C, D). By contrast to mitochondria, peroxiso-
al palmitoyl-CoA oxidase was not changed and only peroxi-
omal catalase activity was induced by AO or OO (Fig. 2A).
hese results support experimentally that AO and OO up-
egulate specifically mitochondrial fatty acid β-oxidation (ex-
ept for the medium chain) and peroxisomal catalase activities
Fig. 2B).
.3. LPS induces selective changes in mitochondrial and
eroxisomal FAOx gene expression
Consistent with previous studies [47,48], treatment with LPS
trongly decreased the expression of nuclear receptors, PPARα
nd ERRα, mRNA levels in mouse liver (Fig. 1A, B). LPS also
ecreased the hepatic expression of mRNA level of PGC-1α.
owever in these conditions, lipin-1, which may interact with
GC-1α [24], showed enhanced mRNA levels (Fig. 1D). Mea-
urements of the expression of mitochondrial and peroxisomal
AOx gene products at two stages (mRNA levels and enzyme ac-
ivities) and 16 h after LPS injection showed a selective decrease
f ACADS without changes in ACOX1, ACADM and ACADVL
RNA expressions (Fig. 1E, F). In addition, LPS treatment led to
reduction of mitochondrial ACADS enzyme activity (Fig. 2C)
nd also, as further discussed, of peroxisomal ACOX1 activity
Fig. 2A), while the activity of peroxisomal catalase was en-
anced (Fig. 2B).
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Fig. 1. Argan oil preserves hepatic mRNA expressions of nuclear receptors PPARα and ERRα, coactivator PGC-1α and target genes during exposure of mice
to LPS. Real-time PCR was used to quantify the hepatic mRNA levels of PPARα (A) and ERRα (B), coactivators PGC-1α (C) and lipin-1 (D) their target
genes: Acox1 (E), Acads, Acadm and Acadvl (F). All real-time PCR reactions were performed in duplicate. All values are means ± SEM (n = 5/group) and
are normalized to control mice. Symbols (∗, # and +) correspond to a statistical significance of higher mean signal intensity, (p < 0.01 for ∗∗∗ and +++,
p < 0.02 for ∗∗ and ++, p < 0.05 for ∗ and #), compared with the control (∗) or with the LPS-treated mice (+). Mice received for 25 days a standard chow
(control); a standard chow supplemented with 6% (w/w) of Argan oil (AO) or a standard chow supplemented with 6% (w/w) of olive oil (OO). Sixteen hours
before euthanasia, one group from control (+LPS), AO (AO + LPS) and OO (OO + LPS) respectively received intraperitoneal injection of 100 μg LPS.
L
s
A
t
(
O
f
v
i
t
(
3
e
g
g
t
a
s3.4. Argan oil protects against the drops induced by LPS in
hepatic expression of PPARα, ERRα and coactivator
PGC-1α
To evaluate the direct therapeutic benefit of Argan oil (AO),
mice were pretreated with AO for 24 days before LPS injec-
tion taking place 16 h prior to euthanasia. The effects of AO
were compared to those of OO, and as illustrated by Fig. 1A,
preserved levels of PPARα mRNA were observed in AO + LPS-
treated mouse livers, being comparable to protection observed in
livers from OO + LPS-treated mice (Fig. 1A). By contrast, only
AO + LPS induced substantial significant increases in liver ex-
pression of ERRα and PGC-1α mRNA when compared to LPS
alone, while OO + LPS induced only a modest significant in-
crease in PGC-1α mRNA level (Fig. 1B and C). At the opposite,
pretreatment with AO + LPS showed an equal increase in lev-
els of Lipin-1 mRNA as in LPS group, revealing no effect of
AO. However, combined OO pretreatment and LPS injury re-
duced significantly the expression of Lipin-1 mRNA (Fig. 1D).
Evaluation of mRNA levels of PPARα target genes involved in
mitochondrial and peroxisomal FAOx (Fig. 1E, F) showed thatPS provoked only a decrease in ACADS mRNA, being without
ignificant effects on mRNA levels of ACADM, ACADVL and
COX1. Measurements of FAOx enzyme activities revealed that
he selective reduction by LPS treatment of ACOX1 and ACADS
C4:0) activities were prevented by AO or OO (AO + LPS or
O + LPS), while for the other dehydrogenase activities, no ef-
ects of the oils were observed except for C16:0 with AO + LPS
ersus LPS (Fig. 2A, C and D). The enhanced activity of perox-
somal catalase, after LPS treatment, was preserved by OO pre-
reatment (OO + LPS) and to a lesser extent by AO (AO + LPS)
Fig. 2B).
.5. Argan oil preserves hepatic gluconeogenesis gene
xpressions during LPS-induced liver dysfunction
HNF4α is a critical nuclear receptor of PGC-1α-mediated
luconeogenesis and controls the expression of gluconeogenic
enes (PEPCK, G6PH) [31]. Here we showed that AO and OO
reatments had no effect on the mRNA level of HNF4α, and 16 h
fter LPS administration, there was still no change in the expres-
ion of HNF4α (Fig. 3A), though the expression of its known
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Fig. 2. Argan oil protects hepatic mitochondrial and peroxisomal fatty acid oxidation during exposure of mice to LPS. The specific activities of mitochondrial
acyl-CoA dehydrogenases (SCAD, MCAD, LCAD and VLCAD) and peroxisomal enzymes (ACOX1 and Catalase) were measured in liver homogenates as
described in “Material and Methods” section. All values are means ± SEM (n = 5/group). Symbols (∗, # and +) correspond to a statistical significance of
higher mean signal intensity (p < 0.01 for ∗∗∗, ¤¤¤ and ###; p < 0.02 for ∗∗, ## and ++; p < 0.05 for ∗, ¤ and #), compared with the control mice (∗) or
with the LPS-treated mice (+). Mice received for 25 days a standard chow (control); a standard chow supplemented with 6% (w/w) of Argan oil (AO) or a
standard chow supplemented with 6% (w/w) of olive oil (OO). Sixteen hours before euthanasia, one group from control (+LPS), AO (AO + LPS) and OO
(OO + LPS) respectively received intraperitoneal injection of 100 μg LPS.
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earget genes were induced to different extents by AO and OO
reatments. Indeed, AO up-regulated the expression of PEPCK,
6PH and Glut2 mRNA, while OO, PEPCK and Glut4 mRNA
evels (Fig. 3B). Finally, administration of LPS deeply reduced
he mRNA expression of these four target genes (Fig. 3B). Inter-
stingly, AO + LPS-treated mice exhibited preservation of liver
luconeogenic gene expressions, particularly PEPCK, G6PH
nd Glut4, which were kept quasi-normal. However, the expres-
ion of Glut2, the highly expressed glucose transporter in liver,
as more deceased in AO + LPS-treated compared to LPS-
reated mice (Fig. 3B). OO + LPS-treated mice exhibited also
revention towards LPS-downregulation of liver gluconeogenic
enes and no protection for Glut4 was induced by OO (Fig. 3B).
. Discussion
The present work provides evidence that mice fed with AO
ave enhanced expressions of several hepatic FAOx and gluco-
eogenesis transcripts and this AO-mediated upregulation per-
ists during endotoxic LPS shock. This protective effect appears
o associate coregulations of hepatic nuclear receptors PPARα,
RRα and HNF-4α and their coactivator PGC-1α [31]. In ad-
ition, AO seems to have specific effects on the activities of
itochondrial acyl-CoA dehydrogenases and peroxisomal cata-
ase.
.1. AO and OO vs control diets
The body weight of mice fed dietary Argan oil or olive oil
id not show any significant difference in comparison to theody weight found in mice fed the control diet. Although data
n mice fed Argan oil are absents in the literature, 10% diet
upplementation by AO or OO in rat during 4 weeks also showed
o significant differences [49].
In the absence of LPS, AO increases mRNA expression of
PARα and of its mitochondrial (ACADS, ACADM) and per-
xisomal (ACOX1) target genes. Regarding OO treatment, we
btained similar results as with AO for ACADM and ACOX1
RNA. Even if these oils have different fatty acid composi-
ions, AO and OO induced almost a similar induction of PPARα
nd its target genes. As mentioned above, OO contains mainly
bout 70% of oleic acid and only 6–9% of linoleic acid, while
O harbors 35% of linoleic acid and 45% of oleic acid, indicat-
ng that AO is richer in polyunsaturated fatty acids [42]. FAOx
nduction by OO has been shown to be dependent on PPARα,
ince induction by OO or fish oil of hepatic ACOX1 mRNA is
brogated in Pparα null mice [50]. In this respect, several fatty
cids and their polyunsaturated derivatives have been shown
o activate responsive element of PPARα target genes and the
eneration of Pparα null mice established that PPARα coordi-
ates transcriptional activation of the genes coding for proteins
atalyzing FAOx pathways [14,51–53]. Furthermore, at the en-
rgetic level fatty acids are more essential than glucose to the
daptation-phase responses in acute or chronic systemic inflam-
atory diseases [54]. Thus, it will be of interest to compare in
he future the potential preventive effect of supplementing AO
o curative properties of its parenteral administration during a
eptic shock.
On the other hand, though AO or OO increases mRNA
xpression of mitochondrial acyl-CoA dehydrogenases and
56 R. El Kebbaj et al. /Biochimie Open 1 (2015) 51–59
Fig. 3. Argan oil maintains hepatic gluconeogenesis during exposure of mice to LPS- Real-time PCR was used to quantify the hepatic mRNA levels of
HNF-4α (A) and PEPCK, G6PH and Glut4 (B). All real-time PCR reactions were performed in duplicate. All values are means ± SEM (n = 5/group) and
are normalized to control mice. Symbols (∗, §, £ and a) correspond to a statistical significance of higher mean signal intensity, (p < 0.01 for ∗∗∗, £££ and
§§§; p < 0.02 for ∗∗, §§ and b; p < 0.05 for ∗, £ and §), compared with the control mice (∗, §, £) or with the LPS-treated mice (a and b). Mice received
for 25 days a standard chow (control); a standard chow supplemented with 6% (w/w) of Argan oil (AO) or a standard chow supplemented with 6% (w/w) of
olive oil (OO). Sixteen hours before euthanasia, one group from control (+LPS), AO (AO + LPS) and OO (OO + LPS) respectively received intraperitoneal
injection of 100 μg LPS.
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fperoxisomal ACOX1, only mitochondrial oxidation of C4:0,
C12:0 and C16:0 acyl-CoA esters and not peroxisomal
palmitoyl-CoA oxidase activity were increased. Acyl-CoA ox-
idase is long known to bind weakly its flavine adenine dinu-
cleotide (FAD) [50,55] and this might contribute to intraperox-
isomal dissociation of holoenzyme into FAD and apoenzyme
(less stable than holoenzyme). Mitochondrial matrix contains a
FAD synthetase [56] and, therefore, might better secure protein
need in FAD, and hence a better stability of acyl-CoA dehy-
drogenases by favoring holoenzyme vs apoenzyme forms. In
addition, absence of the induction of mitochondrial octanoyl-
CoA (C8:0) dehydrogenase activity by different treatments may
be related to the process of fatty acid degradations in mitochon-
dria and peroxisomes respectively [53]. Thus, the already known
incomplete chain shortening of fatty acyl-CoA in peroxisomes
would participate to the octanoyl-CoA export for replenishment
of the mitochondrial pool [53].
By contrast to OO, gene expressions of both PGC-1α
and Lipin-1 were down regulated by AO. Such effects might
explain the observation of Berrougui et al. [57] that AO dimin-
ished both LDL and TG according to the key role of Lipin-1 in
the assembly and secretion of hepatic very low-density lipopro-
tein and the increase of TG synthesis as well [58]..2. LPS + AO and LPS + OO vs control + LPS diets
In rodents, previous studies have shown that LPS (after a
ingle bolus) induced similar cytokines profiles in either fed or
8 h-fasted rats [59]. Accordingly, given that 24 h-fasting per
e significantly enhances hepatic PPARα mRNA expression and
ctivity [60] and due to its potent anorexigenic effect, LPS has
een injected during the fed state [61].
For the first time, AO is shown to enhance gene expressions
f hepatic FAOx and gluconeogenesis in a way persisting dur-
ng endotoxic LPS shock. This protective mechanism appears
o involve coregulation by PGC-1α of hepatic nuclear recep-
ors PPARα, ERRα and HNF-4α [27]. The present work also
eports that AO and OO increase liver expression of gluco-
eogenic genes. Hepatic gluconeogenesis is regulated by PGC-
α through the coactivation of HNF-4α [31]. Prevention of the
PS-associated downregulation of gluconeogenic genes is bet-
er accounted for by PGC-1α than by HNF-4α without ruling out
ipin-1 activation. Under Lipin-1 RNAi, PEPCK and G6PH are
ndeed down regulated [62]. Dysregulation of lipid metabolism
y LPS injection is characterized by a dramatic decrease in
itochondrial fatty acid oxidative enzymes [63] and hence
atty acid oxidation (FAOx) in several tissues, including liver
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[3,6–10]. Proposed underlying mechanisms include a reduction
n PPARα and its coactivator PGC-1α expressions and hence in
RNA levels of FAOx genes [3,47,48]. Additionally, we showed
strong decrease of ERRα mRNA and increase in liver Lipin-1
ranscripts after LPS treatment. Interestingly, both ERRα and
ipin-1 play key roles in the expression of FAOx genes [48,64].
PS decreases Lipin-1 mRNA in mouse adipose tissue but not
keletal muscle [64] and ERRα in liver, heart, and kidney of mice
arkedly during the LPS-induced acute-response phase [48]. In-
riguingly, AO supplementation in LPS treated mice here has no
ffect on the level of Lipin-1 mRNA, in contrast to OO sup-
lementation which prevents enhancement of Lipin-1 mRNA
y LPS. Such differential effect between AO and OO is simi-
ar to what we obtained for PGC-1α transcripts. Knowing that
ipin-1 RNAi has been shown to mediate reduction of PGC-
α mRNA [62], we could suggest that increase in Lipin-1 may
articipate to the preservation of PGC-1α mRNA by AO. Our
esults corroborate and extend previous studies demonstrating
hat suppression by LPS of FAOx addresses, particularly in liver,
eroxisomal ACOX1 and ACADS genes. Such LPS suppres-
ive effect is prevented by nutritional supplementation with AO,
hich also preserves the gene expressions of ERRα, PPARα and
heir coactivator PGC-1α.
LPS treatment exhibited an opposite effect on peroxisomal
eta-oxidation and antioxidant activities, which were decreased
or ACOX1 and increased for catalase respectively. This may be
elated to the fact that ACOX1 is an H2O2-generating enzyme,
hile catalase is an H2O2-degrading enzyme [52,53]. The LPS-
ssociated generation of reactive oxygen species is believed to
lay a key role during the pathogenesis of sepsis [65]. Accord-
ngly, the inhibition of catalase was associated with the pro-
ression of LPS/D-galactosamine-induced fulminant liver injury
66]. Thus, the preservation of catalase activity by AO may have
protective effect against the exacerbation of liver injury during
PS-induced endotoxemia.
. Conclusion
In conclusion, the present work showed that Argan oil pro-
ects against the decreased expression of genes involved in hep-
tic FAOx and gluconeogenesis usually observed during the
cute response phase associated with LPS administration. This
reventive protection might be related to the recovery of the gene
xpressions of nuclear receptors PPARα and ERRα as well as
f their coactivator PGC-1α. Such recovery may explain the
reservations of mitochondrial and peroxisomal enzymatic ac-
ivities in parallel to an improvement of gluconeogenic gene
xpressions.
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